Sono-Tek Corporation (NASDAQ: SOTK) — Q1 FY2025 Form 10-Q
Business context and period: The company designs and manufactures ultrasonic coating systems for microelectronics, clean energy, medical, industrial and other markets. This unaudited quarter covers the three months ended May 31, 2024; comparisons are with the three months ended May 31, 2023 unless otherwise stated.
Financial performance and liquidity
| Metric | Q1 FY2025 | Prior-year quarter | Change |
|---|---|---|---|
| Net sales | $5.03 million | $3.60 million | Up 40% |
| Gross profit / margin | $2.45 million / 48.8% | $1.78 million / 49.3% | Profit up 38%; margin down 0.5 percentage points |
| Operating income (loss) | $238,000 | ($92,000) | Improved $330,000 |
| Net income | $331,000 | $53,000 | Up $278,000 |
| Basic and diluted EPS | $0.02 | $0.00 | Improved |
| Cash from operating activities | $328,000 | $828,000 | Down $500,000 |
Operating expenses rose 19% to $2.22 million, including higher research and development, selling, and general and administrative costs. Interest and dividend income plus unrealized gains on marketable securities totaled approximately $153,000, compared with approximately $124,000 a year earlier; management attributed the increase primarily to the higher interest-rate environment.
At May 31, 2024, cash and cash equivalents were $2.40 million and marketable securities were $9.75 million, totaling approximately $12.15 million. The company reported no outstanding debt. Working capital was $12.49 million, up from $12.12 million at February 29, 2024. The $1.5 million revolving credit line and $750,000 equipment line were undrawn. Cash and cash equivalents increased $267,000 during the quarter.
Total assets were $23.55 million and stockholders’ equity was $16.66 million at May 31, 2024. Inventory was $5.48 million. Customer deposits, a contract liability, were $3.34 million; approximately $2.10 million of prior-period deposits were recognized as revenue during the quarter. The company disclosed $2.01 million of bank deposits above the FDIC-insured limit.
Material changes and business trends
- Growth was driven by shipments to medical and alternative/clean energy customers. Alternative energy/clean energy sales rose 174% to $2.28 million, and medical sales rose 124% to $857,000. Industrial sales fell 65% to $313,000, while electronics/microelectronics sales rose 14% to $1.57 million.
- Multi-axis coating systems generated $2.66 million, up 51%; integrated coating systems generated $747,000, up 142%. Fluxing systems fell 43% to $134,000. Management cited specific large equipment shipments as contributors to the quarter’s results.
- Foreign sales were $1.94 million, or 39% of revenue, versus $1.24 million, or 34%, in the prior-year quarter. EMEA sales rose 192% to $1.25 million.
- Gross margin declined as some costs were reclassified from research and development to cost of goods sold following completed R&D projects. General and administrative expense also reflects the reclassification of the CEO’s compensation from selling expense.
- Equipment backlog was $7.69 million at May 31, down 15.4% from February 29; equipment and service backlog was $7.83 million, down 16%. Management cautioned that large, high-average-selling-price orders can make revenue and backlog fluctuate substantially between quarters.
Outlook, commentary and risks
No quantified revenue or earnings guidance is provided in the filing. Management expects industrial sales to rebound in Q2 based on existing backlog and said it hopes fluxing-system sales will recover in the second half of FY2025 following changes to distribution channels; it cautioned that the fluxing recovery is not assured. Management also described continued growth initiatives in clean energy, medical markets, sales coverage and product development.
Management identified risks including economic and market conditions, inflation and supply-chain pressures, tariffs, customer acceptance and validation of new products, order timing and completion of large projects, maintaining backlog and operating leverage, financing adequacy, and the transition toward more complex, higher-value systems. A single customer represented 15% of quarterly sales; one customer represented 13% of accounts receivable at quarter-end. The company reported no material commitments or contingencies and no pending legal actions. It stated that there were no material changes to previously disclosed risk factors. Disclosure controls were assessed as effective, with no material change in internal control over financial reporting during the quarter.
Investor verification priorities
- Track conversion of the $7.83 million equipment-and-service backlog into shipments and revenue, given quarter-to-quarter variability.
- Verify whether anticipated Q2 industrial recovery and second-half fluxing improvement materialize.
- Monitor gross margin after the R&D-to-cost-of-goods-sold reclassification and the effect of rising operating expenses.
- Compare operating cash generation with reported earnings; operating cash flow fell despite higher net income, with inventory investment and lower customer deposits among the cash-flow factors.
- Assess customer and geographic concentration, including the 15% customer sales exposure, 39% foreign-sales mix and uninsured bank deposits.